182 related articles for article (PubMed ID: 20350191)
1. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
Wilck MB; Seaman MS; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Kleinjan JA; Noble LC; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1361-70. PubMed ID: 20350191
[TBL] [Abstract][Full Text] [Related]
2. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Seaman MS; Wilck MB; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Noble LC; Kleinjan JA; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1353-60. PubMed ID: 20350190
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P; Keitel W; Hill H; Goll JB; Anderson EL; Graham IL; Johnston C; Mulligan M; Rouphael N; Atmar R; Patel S; Chen W; Kotloff K; Creech CB; Chaplin P; Belshe RB
Vaccine; 2015 Sep; 33(39):5225-34. PubMed ID: 26143613
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
6. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
8. Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses.
Frey SE; Stapleton JT; Ballas ZK; Rasmussen WL; Kaufman TM; Blevins TP; Jensen TL; Davies DH; Tary-Lehmann M; Chaplin P; Hill H; Goll JB;
J Infect Dis; 2021 Oct; 224(8):1372-1382. PubMed ID: 33675226
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Frey SE; Winokur PL; Salata RA; El-Kamary SS; Turley CB; Walter EB; Hay CM; Newman FK; Hill HR; Zhang Y; Chaplin P; Tary-Lehmann M; Belshe RB
Vaccine; 2013 Jun; 31(29):3025-33. PubMed ID: 23664987
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
12. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response.
Rosenbaum P; Tchitchek N; Joly C; Rodriguez Pozo A; Stimmer L; Langlois S; Hocini H; Gosse L; Pejoski D; Cosma A; Beignon AS; Dereuddre-Bosquet N; Levy Y; Le Grand R; Martinon F
Front Immunol; 2021; 12():645210. PubMed ID: 33959127
[TBL] [Abstract][Full Text] [Related]
13. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain.
Lu B; Yu W; Huang X; Wang H; Liu L; Chen Z
J Biomed Biotechnol; 2011; 2011():970424. PubMed ID: 21765641
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
[TBL] [Abstract][Full Text] [Related]
18. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
